Skip to content
Moricizine
Ethmozine (moricizine) is a small molecule pharmaceutical. Moricizine was first approved as Ethmozine on 1990-06-19. It is used to treat cardiac arrhythmias, ventricular fibrillation, and ventricular tachycardia in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Moricizine hydrochloride
Tradename
Company
Number
Date
Products
ETHMOZINEShireN-019753 DISCN1990-06-19
3 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
cardiac arrhythmiasEFO_0004269D001145I49.9
ventricular fibrillationEFO_0004287D014693I49.01
ventricular tachycardiaD017180I47.2
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
C01: Cardiac therapy drugs
C01B: Antiarrhythmics, class i and iii
C01BG: Other antiarrhythmics, class i and iii in atc
C01BG01: Moracizine
HCPCS
No data
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SchizophreniaD012559EFO_0000692F2011
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Attention deficit disorder with hyperactivityD001289EFO_0003888F901449
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Conduct disorderD019955EFO_0004216F9111
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMORICIZINE
INNmoracizine
Description
Moricizine is a phenothiazine substituted on the nitrogen by a 3-(morpholin-4-yl)propanoyl group, and at position 2 by an (ethoxycarbonyl)amino group. It has a role as an anti-arrhythmia drug. It is a member of phenothiazines, a member of morpholines and a carbamate ester.
Classification
Small molecule
Drug class
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCOC(=O)Nc1ccc2c(c1)N(C(=O)CCN1CCOCC1)c1ccccc1S2
Identifiers
PDB
CAS-ID31883-05-3
RxCUI40169
ChEMBL IDCHEMBL1075
ChEBI ID6997
PubChem CID34633
DrugBankDB00680
UNII ID2GT1D0TMX1 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 268 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
255 adverse events reported
View more details